Department of Hepatobiliary Surgery, the First People's Hospital of Wenling, Taizhou, China.
Eur Rev Med Pharmacol Sci. 2018 Oct;22(20):6778-6783. doi: 10.26355/eurrev_201810_16144.
To explore the effects of interventional therapy on human immunodeficiency virus (HIV)-1 Tat interactive protein 2/Tat interactive protein 30 (HTATIP2/TIP30), B7-H4 and short-term curative effect in primary hepatocellular carcinoma.
62 patients with primary hepatocellular carcinoma admitted in our hospital from June 2015 to June 2016 were enrolled in this study and divided into observation group (n = 31) and control group (n = 31) according to the random number table. The patients in the control group were treated with radiofrequency ablation, and the patients in the observation group were treated with transcatheter arterial chemoembolization (TACE). The patients in both groups received liver protection therapy, hydration, antiemetic and stomach protection. The curative effects, the serum HTATIP2/TIP30, B7-H4, alanine aminotransferase (ALT) and total bilirubin in serum (TBIL), life quality before and after treatment, and survival during the 1-year follow-up, were compared.
The total short-term effective rate (70.97%) was higher than the control group (38.71%) (p < 0.05). The serum levels of HTATIP2/TIP30 and B7-H4 were decreased after treatment in both groups (observation group: t = 17.1838, 18.9795, control group: t = 8.3787, 10.6393, p < 0.05). The serum levels of HTATIP2/TIP30 and B7-H4 after treatment in the observation group were lower than the control group (t = 12.2975, 10.5361, p < 0.05). The levels of ALT and TBIL were decreased after treatment (observation group: t = 15.1716, 34.5771, control group: t = 8.3374, 17.3015, p < 0.05). The levels of ALT and TBIL were lower in the observation groups than the control group (t = 15.2697, 16.8592, p < 0.05). The improvement rate of life quality in the observation group (80.65%) was higher than the control group (54.84%) (p < 0.05). The survival rates of the two groups after 1-year follow-up were not statistically different (p > 0.05).
The short-term curative effect of interventional therapy of primary hepatocellular carcinoma is good. It can decrease serum HTATIP2/TIP30 and B7-H4, improves the liver function and the life quality of patients, prolonging the survival time. It has a high research value and it is worthy of further application.
探讨介入治疗对人类免疫缺陷病毒（HIV）-1Tat 相互作用蛋白 2/Tat 相互作用蛋白 30（HTATIP2/TIP30）、B7-H4 的影响及对原发性肝癌的近期疗效。
选取 2015 年 6 月至 2016 年 6 月我院收治的原发性肝癌患者 62 例，采用随机数字表法分为观察组（n=31）和对照组（n=31）。对照组采用射频消融治疗，观察组采用肝动脉化疗栓塞术（TACE）治疗。两组患者均给予保肝、水化、止吐、护胃等对症支持治疗。比较两组患者的近期疗效、治疗前后血清 HTATIP2/TIP30、B7-H4、丙氨酸氨基转移酶（ALT）及总胆红素（TBIL）水平、治疗前后生活质量、1 年随访期间生存情况。
观察组总近期有效率（70.97%）高于对照组（38.71%）（P＜0.05）。两组治疗后血清 HTATIP2/TIP30、B7-H4 水平均降低（观察组：t=17.1838、18.9795，对照组：t=8.3787、10.6393，P＜0.05），观察组治疗后血清 HTATIP2/TIP30、B7-H4 水平均低于对照组（t=12.2975、10.5361，P＜0.05）。两组治疗后 ALT、TBIL 水平均降低（观察组：t=15.1716、34.5771，对照组：t=8.3374、17.3015，P＜0.05），观察组 ALT、TBIL 水平均低于对照组（t=15.2697、16.8592，P＜0.05）。观察组生活质量改善率（80.65%）高于对照组（54.84%）（P＜0.05）。两组患者 1 年随访期间生存率比较，差异无统计学意义（P＞0.05）。
原发性肝癌介入治疗近期疗效确切，可降低血清 HTATIP2/TIP30、B7-H4 水平，改善患者肝功能和生活质量，延长生存时间，具有较高的研究价值，值得进一步应用。
